Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Symptom-based adjustment Clear all

Conditions: Asthma
Interventions: Symptom-based adjustment, Biomarker-based adjustment, Guideline-based adjustment; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Acute Coronary Syndrome, Depression
Interventions: Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care; Behavioral · Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 35 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more

Conditions: Stress Disorders, Post-Traumatic, Bulimia Nervosa
Interventions: Prazosin, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Sleep study-guided adjustment of NIV, Standard initiation of NIV; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: Personalized Cardiopulmonary Rehabilitation, Education; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Heart Failure (CHF)
Interventions: Collaborative Care to Alleviate Symptoms and Adjust to Illness, Psychospiritual; Other · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Renal Transplant Candidate
Interventions: Physical Activity; Other
Lead sponsor: Wake Forest University; Other
Eligibility: 60 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Kidney Transplantation
Interventions: Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 38
States / cities: Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more

Conditions: Breast Neoplasms
Interventions: LOFT Therapy; Other
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Head and Neck Cancer
Interventions: A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME); Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Separation Anxiety Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions: Acoustic Neuromodulation (ANM); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Ultrase® MT20; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania

Conditions: Neonatal Abstinence Syndrome
Interventions: Phenobarbital, Clonidine; Drug
Lead sponsor: University of Tennessee Medical Center; Other
Eligibility: 35 Weeks and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Inflammatory Bone Disease
Interventions: Infliximab Assay; Diagnostic Test
Lead sponsor: Cares, Kristen, M.D.; Other
Eligibility: 5 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Bipolar Disorder Depression
Interventions: Lurasidone (Latuda); Drug
Lead sponsor: Martin Lan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort, Cortef, Placebo; Drug · Other
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Parkinson´s Disease
Interventions: Kinesia-ONE™, Kinesia-360™, Rotigotine; Device · Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Fountain Valley, California • Boca Raton, Florida • Winfield, Illinois + 5 more

Conditions: Heart Failure, Acute Heart Failure
Interventions: Protocolized diuretic therapy; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Tiered whole health support for people living with COPD; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Major Depressive Disorder (MDD), Healthy Adult Volunteer
Interventions: Hot Cognitive Task, Cold cognitive tasks, Structural magnetic resonance imaging (sMRI), Magnetoencephalography imaging (MEG), four self-report forms per the requirement of the NIH Common Data Elements project, Four self-report measures to assess interpersonal functioning, Clinical assessments, ATHF; Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Arlington, Texas • Dallas, Texas

Conditions: Radiculopathy, Neck Pain, Spinal Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Intervertebral Disk Displacement
Interventions: Physical therapy rehabilitation; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Lackland Air Force Base, Texas • Salt Lake City, Utah

Conditions: Bipolar II Disorder
Interventions: Interpersonal and Social Rhythm Therapy (IPSRT-BPII), Seroquel; Behavioral · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)

Comparison of Depression Interventions After Acute Coronary Syndrome

Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)

RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

Improving Symptoms and Quality of Life in Chronic Heart Failure: Pilot Study

Physical Activity Program for Older Renal Transplant Candidates

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

Impact of LOFT Therapy™ on Breast Cancer Survivors

A Motion Exergaming Approach for Symptom Management: HNC

RECOVER-ENERGIZE Platform Protocol

Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome

Infliximab Proactive Drug Monitoring in the Pediatric IBD Population

Broadband Near Infrared Spectroscopy to Understand the Role of Brain Cytochrome C Oxidase in Bipolar Disorder

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

Development And Evaluation of An Adaptive Web-Based Intervention for COPD

Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression

The Value of Traction in the Treatment of Cervical Radiculopathy

Psychotherapy for Bipolar II Depression, Pilot Study, Phase II